journal article·2021-08

Tumor Therapy: In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response (Adv. Mater. 31/2021)

Worapol Ngamcherdtrakul, Moataz Reda, Molly A. Nelson, Ruijie Wang, Husam Y. Zaidan, Daniel S. Bejan, Ngoc Ha Hoang, Ryan S. Lane, Shiuh‐Wen Luoh, Sancy A. Leachman, Gordon B. Mills, Joe W. Gray, Amanda W. Lund, Wassana Yantasee

Advanced Materials· Volume 33· Issue 31
Publisher page

Abstract

In article number 2100628, Wassana Yantasee and co-workers investigate how Augmenting Immune Response and Inhibiting Suppressive Environment of tumors-02 (AIRISE-02) activates an antitumor immune response. AIRISE-02 is a nanoparticle co-delivering STAT3 siRNA and CpG intratumorally, utilizing local tumor antigens to train the immune system to kill cancer throughout the body. AIRISE-02 shows strong efficacy in various tumor models, and favorable safety in mice and monkeys.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

PDX Pharmaceuticals, Inc. Portland OR 97239 USA

Department of Biomedical Engineering Oregon Health and Science University Portland OR 97239 USA

Department of Cell, Developmental and Cancer Biology Oregon Health and Science University Portland OR 97239 USA

VA Portland Health Care System Portland OR 97239 USA

Knight Cancer Institute Oregon Health and Science University Portland OR 97239 USA

Department of Dermatology Oregon Health and Science University Portland OR 97239 USA

References

Reference metadata was not supplied for this record.